

Fat Distribution and Major Depressive Disorder in Late Adolescence

William H. Coryell, MD^{a,*}; Brandon D. Butcher, BS^a; Trudy L. Burns, PhD^b;
Lilian N. Dindo, PhD^a; Janet A. Schlechte, MD^c; and Chadi A. Calarge, MD^a

ABSTRACT

Objective: Substantial evidence exists to indicate bidirectional relationships between obesity and depressive disorders and the importance of fat distribution to this relationship. This analysis used a well-characterized sample of individuals in late adolescence to determine the association between depressive illness and fat distribution.

Method: Medically healthy 15- to 20-year-olds, one-half of whom had recently begun treatment with a selective serotonin reuptake inhibitor, underwent a comprehensive psychiatric evaluation that resulted in diagnostic classification and weekly psychiatric disorder ratings over the prior 4 months using the Longitudinal Interval Follow-Up Evaluation. A whole-body scan, using dual-energy x-ray absorptiometry, allowed estimations of total body less head (TBLH), total mass, fat mass, and visceral adipose tissue (VAT) mass. Assessments occurred between September 2010 and April 2014. Multivariable linear regression analyses, adjusted for relevant covariates, examined the association between *DSM-IV-TR*-diagnosed major depressive disorder (MDD) and VAT, the primary outcome of interest. These procedures also determined whether significant associations were confined to overweight/obese participants.

Results: The analysis included data from 200 participants (71% female; mean age = 19.0 ± 1.6 years), of whom 128 had current MDD. The presence of MDD was associated with increased fat mass among overweight/obese participants (Cohen *d* = 0.79, *P* < .02), but not normal weight participants. This was true of both visceral and nonvisceral fat mass measures. Accounting for the presence of generalized anxiety disorder (GAD) did not alter the findings.

Conclusion: In adolescents, relationships between central adiposity and MDD may be confined to those who are overweight/obese. Despite the high comorbidity of GAD and depressive disorders, only the latter appeared to be significantly associated with central adiposity.

J Clin Psychiatry 2016;77(1):84–89
dx.doi.org/10.4088/JCP.14m09169

© Copyright 2015 Physicians Postgraduate Press, Inc.

^aDepartments of Psychiatry, ^bEpidemiology, and ^cInternal Medicine, University of Iowa, Iowa City

*Corresponding author: William H. Coryell, MD, University of Iowa, Carver College of Medicine, Department of Psychiatry Research, 500 Newton Rd, Ste 2-205 MEB, Iowa City, IA 52242-1900 (william-coryell@uiowa.edu).

Studies of both clinic-based^{1–6} and community-based^{7–11} samples have, with some exceptions,^{12–14} demonstrated significant associations between excess body weight and depressive symptoms or disorders. In most reports, central adiposity, whether directly quantified as visceral adipose tissue (VAT)^{1,3,6–9,11,15,16} or indirectly estimated as a waist-to-hip ratio,^{4,5,8,10,17,18} accounted for much or all of the relationship between excessive weight and depressive morbidity. Some reports also found that the relationship between VAT and depressive illness was restricted to, or more robust in, overweight/obese individuals.⁷ Others found that individual depressive symptoms varied in their tendency to promote weight gain such that the strongest associations with obesity were apparent within depressive subtypes (marked by episodes with hyperphagia and hypersomnia [ie, atypical depression]).^{4,19}

The causal relationship between VAT and depressive illness may well be bidirectional. Depressive illness is likely to promote weight gain when symptoms of fatigue and anhedonia result in decreased activity levels or when hyperphagia or medication side effects increase food intake. Hypothalamic-pituitary-adrenal axis hyperactivity, present in many individuals with major depressive disorder (MDD), may also promote VAT deposition because the effects of increased glucocorticoid release on gluconeogenesis are strongest within VAT.²⁰ This association is illustrated by the finding that obese women with high waist-to-hip ratios exhibit more robust cortisol responses to corticotropin-releasing hormone than do obese women with lower waist-to-hip ratios.⁷ In the opposite causal direction, visceral adipocytes produce more cytokines than do subcutaneous ones^{21–24} and are thus more likely to promote depressive illness.^{5,12,25–27}

Accordingly, evidence exists for differing causal models. In 1 investigation²⁸ using linear regression analysis, inflammation, as reflected by C-reactive protein (CRP) concentration, appeared to explain how adiposity (ie, body mass index [BMI]) leads to the emergence of depressive symptoms. In another,⁵ structural equation modeling suggested that depressive symptoms result in weight accumulation that then activates an inflammatory response.

Together, these findings suggest that vicious cycles are at play in individuals who are both overweight and suffering from depressive illness. Indeed, a combination of depressive symptoms and high CRP values has been shown to be a substantially stronger predictor of later obesity than either depressive symptoms or high CRP values individually.²⁹ This interplay is, therefore, likely to have significant implications for long-term psychiatric and cardiovascular morbidity and, thus, to comprise a major public health issue.

The relationship between depressive illness and excess weight in adolescence is particularly important because high BMI in this age group increases the risk of obesity in adulthood as much as 45-fold.³⁰ Moreover, if the association between depressive illness and obesity holds in adolescents, it may have even greater prognostic relevance for

- The relationship between excess body weight and depressive illness is complex and may differ by the distribution of body fat, age, and type of depressive symptoms.
- The results indicate that the likelihood of current major depressive disorder (MDD) increases with fat quantities in overweight but not normal-weight adolescents, regardless of fat distribution.
- In contrast to MDD, generalized anxiety disorder does not appear to be associated with increased adiposity despite its high comorbidity with depressive disorder.
- The findings suggest that efforts directed at weight loss may improve control of depressive symptoms, and vice versa, in overweight adolescents and young adults.

long-term physical health than it does in adult populations. Indeed, Shomaker et al⁶ found that depressive symptoms in childhood are underscored by the observation in 1 cohort that depressive symptoms in childhood predicted decreased insulin sensitivity years later, independent of current BMI. However, the cross-sectional studies that have examined links between obesity and depressive illness in this age group have yielded inconsistent results. Some have identified no association,^{12,13,31} some found an association in one sex but not the other,^{4,27} and some have reported that both boys and girls with a high BMI had more depressive symptoms.^{8,32} Of note, at least some of the variability in the findings may be due to the fact that most, though not all,⁸ studies analyzed BMI, a measure that does not distinguish between adipose and lean mass composition.

Prospective studies can better address the direction of causality between depressive illness and excess weight. Most of these have shown that depressive symptoms during late childhood and adolescence predict later obesity,³³ particularly in girls.^{34,35} In fact, the relationship between depressive disorders and later obesity appears to be stronger when depression develops earlier in life. Conversely, evidence that obesity portends later depressive illness exists as well.^{31,36–38}

In light of these findings, we utilized data from a well-characterized group of individuals in late adolescence to address the following questions: Is increased adiposity in this age group associated with having MDD and is this association stronger for certain depressive symptoms? If so, how much of this relationship is accounted for by VAT? Does the relationship hold across the full range of BMI or is it largely confined to individuals who are overweight/obese? Finally, is excess VAT significantly associated only with MDD or does this association extend to anxiety disorders?

METHOD

Participants

Two-hundred participants, 15 to 20 years old, who were within 1 month of starting a selective serotonin reuptake inhibitor (SSRI; $n = 103$) or who were taking no psychotropics, were enrolled from outpatient and inpatient

clinical settings, as well as by e-mail solicitation and word of mouth, into an ongoing longitudinal observational study examining the skeletal effects of SSRIs. Treatment with other psychotropic medications during the 2 years prior to study entry led to exclusion, with the exception of benzodiazepines, antihistaminic agents, trazodone, α_2 -agonists, mirtazapine, or a stable dose of psychostimulants. Other grounds for exclusion were the presence of eating disorders, substance dependence, pregnancy, significant medical or surgical history, the chronic use of medications potentially affecting bone metabolism (eg, extended corticosteroid use), or plans to move out of state in the following year. The University of Iowa Institutional Review Board approved the study and adult participants provided informed consent. The parent/guardian of minor participants provided written informed consent while the minors gave written assent to the study. Assessments occurred between September 2010 and April 2014.

Procedures

Trained research coordinators collected demographic and clinical data in an intake assessment battery that included the Inventory for Depressive Symptomatology (IDS).³⁹ The participants were also queried about their use of alcohol, nicotine, and illicit substances. Subjects completed the Physical Activity Questionnaire for Older Children, an instrument that quantified physical activity over the preceding week⁴⁰ and described their recent food intake with the Food Questionnaire (Block 2005.1) (<http://www.NutritionQuest.com>).

Trained nursing staff at the Clinical Research Unit of the University of Iowa obtained the anthropometric measurements. Height was measured to the nearest 0.1 cm using a stadiometer (Holtain Ltd, United Kingdom) while standing erect without shoes, and weight was recorded to the nearest 0.1 kg using a digital scale (Scaletronix, Wheaton, Illinois) while wearing indoor clothes. Participants were categorized as being overweight/obese if their BMI was ≥ 30 kg/m² or their age- and sex- specific BMI percentile was ≥ 95 . The threshold for being underweight was a BMI < 18 kg/m² or BMI percentile < 5 . The medical records for the year preceding study enrollment were reviewed to extract relevant clinical information, including available anthropometric measurements.

Diagnoses, based on the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision,⁴¹ incorporated information from the review of medical records and the self- and researcher-completed symptom rating scales, the National Institute of Mental Health Diagnostic Interview Schedule for Children (DISC-IV),⁴² and an unstructured interview by a child psychiatrist (C.A.C.). Parents were not interviewed.

Symptoms of MDD over the 4 months preceding intake were quantified for each week using the Longitudinal Interval Follow-Up Evaluation,⁴³ modified for use with adolescents (A-LIFE). The A-LIFE is commonly used in longitudinal studies as it allows estimation of both the duration and

It is illegal to post this copyrighted PDF on any website.

Table 1. Demographic and Clinical Characteristics by Lifetime History of MDD^a

| Characteristic | Total Sample (N = 200) | MDD (n = 128) | No MDD (n = 72) | P Value |
|------------------------------------|---------------------------|------------------|--------------------|------------------|
| Female, n (%) | 142 (71) | 99 (77) | 43 (60) | <.01 |
| Age, y | 19.0 ± 1.6 | 18.9 ± 1.6 | 19.1 ± 1.4 | >.30 |
| Caucasian, n (%) | 175 (88) | 112 (88) | 63 (88) | >.90 |
| Hispanic, n (%) | 16 (8) | 13 (10) | 3 (4) | >.10 |
| Physical activity score | 2.1 ± 0.8 | 2.1 ± 0.8 | 2.2 ± 0.8 | >.50 |
| Calorie intake, kcal/d | 1378 ± 916 | 1679 ± 870 | 1,840 ± 988 | >.10 |
| Taking SSRI, n (%) | 103 (52) | 98 (77) | 10 (14) | <.0001 |
| GAD, n (%) | 64 (32) | 51 (40) | 13 (18) | <.0001 |
| Alcohol abuse, n (%) | 24 (12) | 14 (11) | 10 (14) | >.50 |
| Cigarette use, n (%) | 30 (15) | 18 (14) | 12 (17) | >.60 |
| Cigarettes, d | 2.6 ± 4.1 | 3.1 ± 5.0 | 1.9 ± 2.2 | >.90 |
| Anthropometric measurements | | | | |
| BMI (kg/m ²) | 24.2 ± 4.8 | 24.3 ± 4.5 | 24.2 ± 5.0 | >.40 |
| BMI z score | 0.40 ± 0.92 | 0.39 ± 0.92 | 0.42 ± 0.93 | >.60 |
| Overweight/obese, n (%) | 65 (33) | 36 (28) | 29 (40) | <.10 |
| Waist circumference (cm) | 89.0 ± 13.0 | 89.3 ± 12.1 | 88.8 ± 13.6 | >.50 |
| TBLH mass (kg) | 64.6 ± 14.9 | 64.1 ± 14.5 | 65.5 ± 15.7 | >.60 |
| TBLH lean mass (kg) | 46.0 ± 9.7 | 45.1 ± 8.6 | 47.6 ± 11.3 | >.10 |
| LBMI z score | -0.12 ± 0.85 | -0.10 ± 0.84 | -0.15 ± 0.88 | >.70 |
| TBLH fat mass (kg) | 18.6 ± 9.5 | 19.0 ± 9.9 | 17.9 ± 8.9 | >.50 |
| FMI z score | -0.11 ± 0.87 | -0.13 ± 0.90 | -0.06 ± 0.83 | >.50 |
| Limb fat mass (kg) | 10.6 ± 4.8 | 10.8 ± 5.0 | 10.0 ± 4.5 | >.20 |
| Gynoid fat mass (kg) | 1.3 ± 0.9 | 1.4 ± 0.9 | 1.3 ± 0.8 | >.90 |
| Android fat mass (kg) | 3.9 ± 1.6 | 4.0 ± 1.7 | 3.7 ± 1.5 | >.30 |
| Visceral adipose tissue mass (kg) | 0.26 ± 0.15 | 0.26 ± 0.17 | 0.26 ± 0.12 | >.40 |

^aAll values are mean ± SD unless otherwise stated. Bold indicates $P < .10$.

Abbreviations: BMI = body mass index, FMI = fat mass index, GAD = generalized anxiety disorder, LBMI = lean body mass index, MDD = major depressive disorder, SSRI = selective serotonin reuptake inhibitor, TBLH = total body less head.

the severity of individual disorders.⁴⁴ It identifies change points anchored by memorable dates such as holidays or the beginnings of academic semesters. For mood and anxiety disorders, the A-LIFE psychiatric status rating scores range from 1 for no symptoms, to 2 to 4 for varying levels of symptom severity and impairment, and to 5 and 6 for full criteria. Comorbid phenomena, such as substance use disorders, are also scored on a weekly basis on a 3-point Likert scale with 1 reflecting the absence of symptoms and 3 indicating a threshold level. A prior history of the corresponding disorder was not required for the rating to be made, so that subthreshold symptoms were rated even in the absence of a previous or current full episode.

A whole-body, dual-energy x-ray absorptiometry (DXA) scan was obtained using a Hologic Discovery A unit (Hologic Inc, Bedford, Massachusetts), software package APEX 4.0.1/13.4.1. DXA-based VAT measurements have been validated in adults and shown to be equivalent to measurements obtained using computed tomography.⁴⁵ The Hologic software also determined total body less head (TBLH) mass, lean mass, fat mass, gynoid mass, android mass, and waist circumference. Android and gynoid measures quantified the fat amounts in waist and hip areas, respectively.

Data Analysis

Four individuals were excluded from the analysis, 2 who were diagnosed with a probable psychotic disorder and 2 who were underweight. Because relationships between adiposity and depressive illness were likely to be more meaningful and robust when depressive symptoms were current, 18 participants who had

only a past history of major depressive episodes were excluded. All of these had been in full remission for 3.0 ± 2.5 years.

Body mass index was computed as weight/height² (kg/m²), and BMI age- and sex-specific z scores were generated based on the 2000 Centers for Disease Control and Prevention normative data.⁴⁶ Total body less head fat and lean scores were computed as the fat or lean mass minus the mass of the head/height² (kg/m²). Lean body mass index and fat mass index age- and sex-specific z scores were generated based on the 1999–2004 National Health and Nutrition Examination Survey.⁴⁷

The Student *t* test and the χ^2 or Fisher exact test were used to compare continuous and categorical variables across participants with versus without MDD. Multivariable linear regression analysis was used to examine the association between MDD and VAT mass, the primary outcome of interest, as well as adiposity-related variables. Adjustments were made for age, sex, and height; the latter accounting for differences related to body frame size.⁴⁸ Additionally, in order to examine whether the findings were specific to MDD, the presence of generalized anxiety disorder (GAD) was also included in the model. Further, additional analyses examined the association between adiposity variables and the proportion of weeks during the 4 months prior to study entry in which MDD ratings indicated meeting diagnostic criteria (ie, rating of 5 or 6). The presence of reverse vegetative symptoms (hypersomnia or hyperphagia) in the week preceding study entry was taken from the IDS and also examined for its association with increased central adiposity. Because the association between adiposity and depressive illness has been confined to overweight individuals in some studies,⁷ we also tested for an interaction effect between the depression measures and the presence or absence of overweight/obesity (referred to as obesity status, henceforward).

Cohen *d* effect size was the difference in group-specific least squares means (LS means) divided by the residual of the relevant multivariable linear regression model. All hypothesis tests were 2-tailed with a significance level of $P < .05$, and analyses utilized procedures from SAS version 9.3 for Windows (SAS Institute Inc, Cary, North Carolina).

RESULTS

Table 1 summarizes the demographic, clinical, and anthropometric characteristics of the sample. As would be expected, female sex, comorbid GAD, and SSRI use were more prevalent among individuals with MDD. However, no other significant differences between the 2 MDD groups emerged. One-third of the participants were overweight or obese.

Table 2. Fat Distribution Measures^a and Current Diagnoses: Overweight/Obese Participants^b

| Measure | MDD+ | MDD– | Cohen <i>d</i> ^c | GAD+ | GAD– | Cohen <i>d</i> ^c |
|-------------------------|-------|------|-----------------------------|------|-------|-----------------------------|
| VAT fat mass, kg | 0.44 | 0.34 | 0.88 | 0.37 | 0.41 | 0.36 |
| Android fat mass, kg | 2.3 | 1.8 | 0.86 | 2.3 | 1.8 | 0.82 |
| Waist circumference, cm | 104.3 | 97.5 | 0.81 | 97.7 | 104.2 | 0.78 |
| TBLH fat mass, kg | 27.7 | 22.2 | 0.94 | 21.9 | 28.1 | 1.06 |
| Limb fat mass, kg | 14.3 | 11.9 | <u>0.76</u> | 11.7 | 14.6 | 0.90 |
| Gynoid fat mass, kg | 5.2 | 4.4 | <u>0.75</u> | 4.3 | 5.3 | 0.97 |
| TBLH lean mass, kg | 53.9 | 52.5 | 0.34 | 52.7 | 53.7 | 0.26 |

^aLeast squares means.^bSignificant findings ($P < .05$) are bolded, and marginally significant findings ($P < .10$) are underlined.^cAdjusted for age, sex, and height. The differences between lean individuals with versus without MDD and with versus without GAD were not significant.

Symbols: + = presence of the disorder, – = absence of the disorder.

Abbreviations: GAD = generalized anxiety disorder, MDD = major depressive disorder, TBLH = total body less head, VAT = visceral adipose tissue.

Association of MDD and VAT

After adjusting for age ($P > .60$), sex ($P > .60$), and height ($P > .20$), there was a significant interaction effect between obesity status and MDD ($P < .02$) whereby no difference in VAT mass was observed within the normal-weight group between those with MDD and those without ($P > .90$). However, among overweight/obese individuals, the presence of MDD was associated with a larger VAT mass (difference in LS means = 90.7; 95% confidence interval [CI], 11.5 to 169.8; Cohen $d = 0.79$; $P < .02$). Further individual adjustments for calorie intake ($P = .90$), physical activity ($P = .10$), and number of cigarettes smoked each day ($P = .35$) did not alter the findings. Cohen $d = 0.86$ with all 3 variables in the model. To test the possibility that SSRI exposure had itself affected weight measures, we compared the weights of 56 individuals who had been weighed within a month before starting SSRI medication to their weights at study entry. Compared to pretreatment values, the age- and sex-specific BMI z scores had minimally decreased by study entry (mean difference = -0.07 ; 95% CI, -0.12 to -0.02 ; $P < .004$).

Visceral adipose tissue mass, android fat mass, waist circumference, TBLH fat mass, limb fat mass, gynoid fat mass, TBLH lean mass, and BMI z score did not differ by level of reverse vegetative depressive symptoms during the week preceding study entry. For instance, among participants with MDD, those with no hypersomnia or hyperphagia ($n = 45$) had a VAT mass similar to that of those with at least 1 of these 2 symptoms ($n = 83$). Mean VAT mass (kg) values were 0.24 ± 0.15 and 0.28 ± 0.18 ($P = .24$), respectively.

Of interest, the zero-order correlations between VAT mass, on the one hand, and both TBLH fat mass and gynoid fat mass (an index of subcutaneous fat), varied by weight category. Correlations were highly significant for overweight/obese individuals (Spearman $\rho = 0.74$, $P < .0001$ and 0.65 , $P < .0001$) but not for those with normal weights (Spearman $\rho = 0.16$, $P = .06$ and 0.05 , $P > .50$). In contrast, the association between VAT mass and TBLH total mass was more comparable between the 2 obesity status groups (Spearman $\rho = 0.54$ [$P < .0001$] vs Spearman $\rho = 0.69$ [$P < .0001$]).

Impact of GAD on the Association of MDD and VAT

The above multivariable regression analyses were repeated after accounting for the presence of GAD as this is frequently comorbid with MDD and may itself affect metabolic pathways. Again, among

lean participants, the presence of GAD was not related to any of the adiposity variables. However, among the overweight/obese, the presence of GAD was associated with reduced adiposity, except for VAT mass (Table 2). As with MDD, GAD was not associated with lean mass.

DISCUSSION

This study of a group in their late adolescence, enriched for those in a current major depressive episode, showed that MDD in adolescents and young adults who are obese is associated with greater visceral adiposity. We are unaware of studies, other than the 1 cited,⁷ that considered relationships between body fat distribution and depressive symptoms separately in normal-weight and overweight groups. The greater importance of the presence of MDD to fat mass in overweight individuals may be a reflection of the “vicious cycle” posited earlier, perhaps with a threshold effect. If so, adiposity and depressive morbidity may drive each other in at-risk individuals, with increasing intensity as both phenomena worsen. Certainly the earlier findings, together with those described here, indicate that future investigations should separate obese and normal weight individuals as they assess relationships between adiposity and depressive morbidity.

The findings did not support our prediction that relationships between depressive disorder and adiposity would be strongest for measures of visceral fat. However, because associations between visceral fat mass and measures of peripheral fat stores were particularly high in the overweight/obese group, this may have obscured differences in the strengths of the relationships between depressive morbidity and peripheral versus central fat measures.

Although GAD was strongly comorbid with MDD, it was independently associated with adiposity in the overweight/obese groups, though in the opposite direction from its relation to MDD. Hillman et al⁸ likewise found positive relationships between BMI measures and depressive symptoms but not trait anxiety. Anderson et al³⁴ found both anxiety and depressive symptoms to be predictive of later obesity, but because they did not test both in the same model, it was thus not possible to isolate the independent contribution of anxiety disorders. Our finding that depressive morbidity, but not that of GAD, was strongly associated with higher amounts of adiposity despite the frequent coexistence of GAD and MDD is intriguing since it implies that a core set of depressive symptoms is at play and that the relationship to fat distribution is not one simply involving psychiatric morbidity in general. In further support of this specificity is another recent report²

It is illegal to post this copyrighted PDF on any website.

that showed that young women with borderline personality disorder and MDD had higher VAT measures than did healthy controls while those with borderline personality disorder alone did not.

This study's several strengths include the enrollment of young and unmedicated or only recently medicated participants. Extensive psychiatric assessments included carefully determined diagnoses and week-to-week quantifications of symptom severity for MDD and anxiety disorders. Finally, the DXA scans provided validated adiposity measures that specifically isolate VAT.

Chief among the study's limitations is its cross-sectional design. The results cannot be used as evidence for causal relationships between excessive body weight and depressive illness in either direction. A 2-year follow-up is underway, however. Future analyses will address whether high VAT values increase risks for the onset, persistence, or recurrence of MDD and whether the presence or persistence of depressive illness promotes subsequent VAT deposition.

Longitudinal measures of depressive and anxiety disorder morbidity were limited to the 4 months that preceded intake because potential inadequacies of memory would have made morbidity measures over longer periods less dependable. The

ongoing prospective phase will allow a substantially longer view of morbidity.

Inclusion criteria limited ages to 15 through 20 years so as to avoid the greater flux in growth and metabolism that puberty entails. This, of course, precludes the generalizability of these results to younger adolescents and children. We would argue, though, that these age groups should be studied separately given the differences between them, both in anthropometric measures and in the manifestations of depressive illness.

A meta-analysis³³ has shown that relationships between early depressive illness and later obesity are strongest in adolescent depressive disorder. This makes our findings of public health importance because they indicate a particular age period when intervention to lessen eventual cardiovascular morbidity through better weight control might be most useful. Moreover, the possibility that central adiposity promotes the persistence of depressive symptoms in overweight/obese individuals suggests an underlying role for inflammatory mechanisms in the maintenance of depressive disorder and this, in turn, may offer another potential tool in the management of an illness that often results in substantial disability over a lifetime.⁴⁹

Submitted: March 31, 2014; accepted December 15, 2014.

Online first: October 27, 2015.

Drug names: mirtazapine (Remeron and others).

Potential conflicts of interest: The authors report no conflict of interest.

Funding/support: This work was funded by the National Institute of Mental Health (R01MH090072) and the National Center for Research Resources (2UL1TR000442-06).

Role of the sponsor: The funding organizations are public institutions and had no role in the design and conduct of the study; collection, management, and analysis of the data; or preparation, review, and approval of the manuscript.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

REFERENCES

- Eskandari F, Mistry S, Martinez PE, et al; POWER (Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Study Group. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. *Metabolism*. 2005;54(7):918–924.
- Greggerson W, Rudolf S, Fassbinder E, et al. Major depression, borderline personality disorder, and visceral fat content in women. *Eur Arch Psychiatry Clin Neurosci*. 2011;261(8):551–557.
- Ludescher B, Najib A, Baar S, et al. Increase of visceral fat and adrenal gland volume in women with depression: preliminary results of a morphometric MRI study. *Int J Psychiatry Med*. 2008;38(3):229–240.
- Merikangas AK, Mendola P, Pastor PN, et al. The association between major depressive disorder and obesity in US adolescents: results from the 2001–2004 National Health and Nutrition Examination Survey. *J Behav Med*. 2012;35(2):149–154.
- Miller GE, Freedland KE, Carney RM, et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. *Brain Behav Immun*. 2003;17(4):276–285.
- Shomaker LB, Tanofsky-Kraff M, Stern EA, et al. Longitudinal study of depressive symptoms and progression of insulin resistance in youth at risk for adult obesity. *Diabetes Care*. 2011;34(11):2458–2463.
- Everson-Rose SA, Lewis TT, Karavolos K, et al. Depressive symptoms and increased visceral fat in middle-aged women. *Psychosom Med*. 2009;71(4):410–416.
- Hillman JB, Dorn LD, Bin Huang. Association of anxiety and depressive symptoms and adiposity among adolescent females, using dual energy x-ray absorptiometry. *Clin Pediatr (Phila)*. 2010;49(7):671–677.
- Ludescher B, Machann J, Eschweiler GW, et al. Active depression is associated with regional adiposity in the upper abdomen and the neck. *Int J Psychiatry Med*. 2011;41(3):271–280.
- Rivenes AC, Harvey SB, Mykletun A. The relationship between abdominal fat, obesity, and common mental disorders: results from the HUNT study. *J Psychosom Res*. 2009;66(4):269–275.
- Zhao G, Ford ES, Li C, et al. Waist circumference, abdominal obesity, and depression among overweight and obese US adults: National Health and Nutrition Examination Survey 2005–2006. *BMC Psychiatry*. 2011;11(1):130.
- Lamertz CM, Jacobi C, Yassouridis A, et al. Are obese adolescents and young adults at higher risk for mental disorders? a community survey. *Obes Res*. 2002;10(11):1152–1160.
- Renman C, Engström I, Silfverdal SA, et al. Mental health and psychosocial characteristics in adolescent obesity: a population-based case-control study. *Acta Paediatr*. 1999;88(9):998–1003.
- Weber-Hamann B, Werner M, Hentschel F, et al. Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up. *Psychoneuroendocrinology*. 2006;31(3):347–354.
- Lee ES, Kim YH, Beck SH, et al. Depressive mood and abdominal fat distribution in overweight premenopausal women. *Obes Res*. 2005;13(2):320–325.
- Vogelzangs N, Kritchevsky SB, Beekman AT, et al; Health ABC Study. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. *J Clin Psychiatry*. 2010;71(4):391–399.
- Ahlberg AC, Ljung T, Rosmond R, et al. Depression and anxiety symptoms in relation to anthropometry and metabolism in men. *Psychiatry Res*. 2002;112(2):101–110.
- Franko DL, Striegel-Moore RH, Thompson D, et al. Does adolescent depression predict obesity in black and white young adult women? *Psychol Med*. 2005;35(10):1505–1513.
- Levin RD, Davis C, Kaplan AS, et al. Obesity comorbidity in unipolar major depressive disorder: refining the core phenotype. *J Clin Psychiatry*. 2012;73(8):1119–1124.
- Pasquali R, Cantobelli S, Casimir F, et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. *J Clin Endocrinol Metab*. 1993;77(2):341–346.
- Fried M, Muga RO, Misore AO, et al. Malaria elicits type 1 cytokines in the human placenta: IFN-gamma and TNF-alpha associated with pregnancy outcomes. *J Immunol*. 1998;160(5):2523–2530.
- Good M, Newell FM, Haupt LM, et al. TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue—influence of BMI and adipose distribution. *Diab Vasc Dis Res*. 2006;3(1):26–33.
- Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation*. 2007;116(1):39–48.
- Pou KM, Massaro JM, Hoffmann U, et al.

- Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. *Circulation*. 2007;116(11):1234–1241.
25. Incedon E, Wake M, Hay M. Psychological predictors of adiposity: systematic review of longitudinal studies. *Int J Pediatr Obes*. 2011;6(2-2):e1–e11.
 26. McClure HH, Eddy JM, Kjellstrand JM, et al. Child and adolescent affective and behavioral distress and elevated adult body mass index. *Child Psychiatry Hum Dev*. 2012;43(6):837–854.
 27. Rofey DL, Kolko RP, Iosif AM, et al. A longitudinal study of childhood depression and anxiety in relation to weight gain. *Child Psychiatry Hum Dev*. 2009;40(4):517–526.
 28. van Reedt Dortland AK, Vreeburg SA, Giltay EJ, et al. The impact of stress systems and lifestyle on dyslipidemia and obesity in anxiety and depression. *Psychoneuroendocrinology*. 2013;38(2):209–218.
 29. Valtonen MK, Laaksonen DE, Laukkanen JA, et al. Low-grade inflammation and depressive symptoms as predictors of abdominal obesity. *Scand J Public Health*. 2012;40(7):674–680.
 30. Rooney BL, Mathiason MA, Schauburger CW. Predictors of obesity in childhood, adolescence, and adulthood in a birth cohort. *Matern Child Health J*. 2011;15(8):1166–1175.
 31. Pine DS, Cohen P, Brook J, et al. Psychiatric symptoms in adolescence as predictors of obesity in early adulthood: a longitudinal study. *Am J Public Health*. 1997;87(8):1303–1310.
 32. Richardson LP, Garrison MM, Drangsholt M, et al. Associations between depressive symptoms and obesity during puberty. *Gen Hosp Psychiatry*. 2006;28(4):313–320.
 33. Blaine B. Does depression cause obesity? a meta-analysis of longitudinal studies of depression and weight control. *J Health Psychol*. 2008;13(8):1190–1197.
 34. Anderson SE, Cohen P, Naumova EN, et al. Association of depression and anxiety disorders with weight change in a prospective community-based study of children followed up into adulthood. *Arch Pediatr Adolesc Med*. 2006;160(3):285–291.
 35. Richardson LP, Davis R, Poulton R, et al. A longitudinal evaluation of adolescent depression and adult obesity. *Arch Pediatr Adolesc Med*. 2003;157(8):739–745.
 36. Goodman E, Whitaker RC. A prospective study of the role of depression in the development and persistence of adolescent obesity. *Pediatrics*. 2002;110(3):497–504.
 37. Milaneschi Y, Simonsick EM, Vogelzangs N, et al. Health, Aging, and Body Composition Study. Leptin, abdominal obesity, and onset of depression in older men and women. *J Clin Psychiatry*. 2012;73(9):1205–1211.
 38. Sánchez-Villegas A, Pimenta AM, Beunza JJ, et al. Childhood and young adult overweight/obesity and incidence of depression in the SUN project. *Obesity (Silver Spring)*. 2010;18(7):1443–1448.
 39. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. *Psychiatry Res*. 1986;18(1):65–87.
 40. Crocker PR, Bailey DA, Faulkner RA, et al. Measuring general levels of physical activity: preliminary evidence for the Physical Activity Questionnaire for Older Children. *Med Sci Sports Exerc*. 1997;29(10):1344–1349.
 41. American Psychiatric Association. *Diagnostic Criteria from DSM-IV-TR*. Washington, DC: American Psychiatric Association; 2000.
 42. Shaffer D, Fisher P, Lucas CP, et al. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. *J Am Acad Child Adolesc Psychiatry*. 2000;39(1):28–38.
 43. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. *Arch Gen Psychiatry*. 1987;44(6):540–548.
 44. Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. *Arch Gen Psychiatry*. 2006;63(2):175–183.
 45. Micklesfield LK, Goedecke JH, Punyanitya M, et al. Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. *Obesity (Silver Spring)*. 2012;20(5):1109–1114.
 46. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. *Pediatrics*. 2002;109(1):45–60.
 47. Weber DR, Moore RH, Leonard MB, et al. Fat and lean BMI reference curves in children and adolescents and their utility in identifying excess adiposity compared with BMI and percentage body fat. *Am J Clin Nutr*. 2013;98(1):49–56.
 48. Taksali SE, Caprio S, Dziura J, et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. *Diabetes*. 2008;57(2):367–371.
 49. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry*. 2013;70(1):31–41.